Pre-exposure prophylaxis (PrEP) is a preventive strategy involving the use of antiretroviral medications by individuals who are HIV-negative but at substantial risk of contracting the virus. When taken as prescribed, PrEP has been shown to reduce the risk of HIV infection from sexual activity by about 99% and by at least 74% among people who inject drugs.
Gilead's Lenacapavir: A Potential Game-Changer in HIV Prevention
Recent developments in HIV prevention have spotlighted Gilead Sciences' investigational drug, lenacapavir. In a Phase 1 study, a single intramuscular dose of lenacapavir maintained effective drug levels in the blood for over a year, suggesting the potential for once-yearly administration as a PrEP option. The study, involving 40 healthy adults, indicated that lenacapavir was well-tolerated, with most participants experiencing only mild injection site pain that resolved within a week.
These promising results have led Gilead to plan a Phase 3 trial later this year to further evaluate lenacapavir's efficacy and safety as a long-acting PrEP solution. If approved, lenacapavir could address adherence challenges associated with daily PrEP regimens, offering a more convenient option for individuals at risk of HIV.
